Month: July 2021

Figure 1: Plan MapFigure 1: Plan MapFigure 2: Section A-A’Figure 2: Section A-A’Figure 3: Section B-B’Figure 3: Section B-B’Figure 4: Section C-C’Figure 4: Section C-C’TORONTO, July 27, 2021 (GLOBE NEWSWIRE) — Hemlo Explorers Inc. (the “Company”) (TSXV: HMLO) is pleased to provide an update on its drill program at the North Limb project, located 15 km north of the Hemlo Mine near Manitouwadge, Ontario. Highlights:Musher Felsic Horizon: Drillholes NL21-01, -03 and -04 (Section A-A’), NL21-02 (Section B-B’) and NL21-05 (Section C-C’) were drilled on three sections spaced 200 metres apart and intercepted a contiguous gold bearing felsic metavolcanic unit of variable width. These five drillholes were designed to test the down dip...

HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the 2021 BTIG Biotechnology Conference on August 9, 2021, at 9:30 AM ET. Aravive will also be participating in one-on-one meetings at the conference. BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative if you have interest. About AraviveAravive, Inc. is a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases. Aravive’s...

UPPSALA, Sweden, July 27, 2021 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that CORAL, a new collaborative community of scientists, will use the Olink Proteomics platform to identify novel protein biomarkers and biological mechanisms for neurological diseases. CORAL is a new collaborative community of scientists that work on diverse neurological conditions studying blood and cerebrospinal fluid (CSF) on the Olink Proteomics platform to identify novel biomarkers and biological mechanisms for neurological diseases. These biomarkers are required for diagnostic, prognostic, disease monitoring and/or treatment response evaluation. The CORAL activities include external validation and study of cross-disease markers and mechanisms. “Multiple groups are conducting proteomics analyses in CSF and blood....

  – Introduces Millennium Cannabis       – Provides update regarding Millennium Carbon       – Posts Updated Investor Presentation to WebsiteOld Bethpage, New York, July 27, 2021 (GLOBE NEWSWIRE) — Millennium Investment & Acquisition Co. Inc. (ticker: MILC) (“MILC” or the “Company”) today is providing a corporate update including the establishment of its greenhouse cannabis cultivation division, Millennium Cannabis (“MillCann”). Currently, MILC has invested in operating companies with two areas of focus:  1 ) Sustainable cultivation of Cannabis in Greenhouses through Millennium Cannabis       2 ) Sustainable production of Activated Carbon through Millennium CarbonMillennium Cannabis MillCann has identified greenhouse cultivation as the sustainable method for growing cannabis in...

Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes  PLEASANTON, Calif., July 27, 2021 (GLOBE NEWSWIRE) — 10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb). The agreement resolves all outstanding litigation and other proceedings between the two companies across all jurisdictions around the world, and dismissing all infringement claims with prejudice. The agreement grants each company a non-exclusive, worldwide, royalty-bearing license to develop products and services related to single cell analysis. The term of the agreement is for the life of the licensed patents. The cross license excludes products related to spatial analysis and In Situ analysis. It also excludes digital...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the appointment of Dr. Patrice P. Denèfle as Chief Scientific Officer (CSO). Dr. Denèfle will join CENTOGENE on August 16, 2021, succeeding Phil Lambert, who has decided to leave the Company. Dr. Denèfle is a seasoned executive and scientific pioneer with over 35 years of experience at pharmaceutical and biotechnology companies in Europe and the U.S. – spearheading translational R&D to deliver breakthrough treatments to patients. Within his role at CENTOGENE, he will be responsible for overseeing scientific activities to deliver on the Company’s vision and strategy, while driving...

Delivered strong growth, reflecting meaningful economic recovery in most of our markets and the benefits of our diversified, growth-oriented portfolio. Increased full year 2021 financial guidance to reflect second quarter out-performance and a more bullish view of the remainder of the year. Continuing to strategically invest to position TransUnion for long-term sustained growth.CHICAGO, July 27, 2021 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) (the “Company”) today announced financial results for the quarter ended June 30, 2021. Second Quarter 2021 Results Our results for the second quarter of 2021 reflect significant improvements in demand for our services in most of the markets where we operate, including from improving macroeconomic conditions, that impact the comparability of results between periods. Revenue:Total revenue...